WO2026033494 - ENGINEERED PROTEIN M AND ITS USE IN ANTIBODY LABELING
National phase entry is expected:
Publication Number
WO/2026/033494
Publication Date
12.02.2026
International Application No.
PCT/IB2025/058118
International Filing Date
08.08.2025
Title **
[English]
ENGINEERED PROTEIN M AND ITS USE IN ANTIBODY LABELING
[French]
PROTÉINE M MODIFIÉE ET SON UTILISATION DANS LE MARQUAGE D'ANTICORPS
Applicants **
TECHNISCHE UNIVERSITEIT EINDHOVEN
Inventors
MERKX, Maarten
VAN AALEN, Eva Anna
ŚWIETLIKOWSKA, Anna
Priority Data
63/680,803
08.08.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1945 | |
| EPO | Filing, Examination, Granting | 8126 | |
| Japan | Filing, Examination, Granting | 2062 | |
| South Korea | Filing, Examination, Granting | 1883 | |
| USA | Filing, Examination, Granting | 7140 |
Total:
21,156
Contact Us
Abstract[English]
Engineered version of protein M, which binds to both κ and λ light chains and enables the labeling of all IgGs. The disclosed Engineered version of protein M enables the coupling of a wide range of molecules, such as luciferase domains, epitope tags, fluorescent domains, oligonucleotides, reporter enzymes, imaging tags, and small molecules to not only commonly used IgGs, but also chicken IgYs, Fabs, and scFvs, while still preserving effective antigen binding.[French]
La présente invention porte sur une version modifiée d'une protéine M, qui se lie à la fois aux chaînes légères κ et λ et permet le marquage de toutes les IgG. La version modifiée de la protéine M décrite permet le couplage d'une large gamme de molécules, telles que des domaines de luciférase, des étiquettes d'épitope, des domaines fluorescents, des oligonucléotides, des enzymes rapporteurs, des étiquettes d'imagerie et de petites molécules pour non seulement des IgG couramment utilisées, mais également des IgY de poulet, des Fab et des scFv, tout en préservant toujours une liaison efficace à l'antigène.